First in-Human Vaccine Trial for Deadly Nipah Virus Commences with WHO Backing

In a monumental stride towards combating the lethal Nipah virus, Oxford University researchers have embarked on the first human trials for a vaccine designed to thwart this deadly pathogen. Spearheaded by the esteemed Oxford Vaccine Group, the trials signify a critical juncture in the relentless battle against infectious diseases, particularly those with pandemic potential.

ChAdOx1 NipahB Vaccine: A Beacon of Hope

The ChAdOx1 NipahB experimental vaccine is leading the fight against the Nipah virus, which has a high fatality rate of approximately 75%. The vaccine targets this virus, which fruit bats, known carriers of the virus, primarily transmit. These bats can transmit the virus by contacting infected animals like pigs or through person-to-person interaction. Developing an effective vaccine is crucial, given the severity of the virus and its potential for rapid spread. Outbreaks of the Nipah virus have occurred in several Asian countries, including SingaporeMalaysiaBangladesh, and India.

Recognized Priority Disease by WHO

Amid the relentless march of emerging infectious diseases, the Nipah virus has become a priority disease on the global health agenda. Classified as such by the World Health Organization (WHO), the Nipah virus demands urgent attention and concerted research efforts. Despite its initial emergence 25 years ago, outbreaks continue to ravage communities across Asia, with recent incidents in India’s Kerala state serving as poignant reminders of the virus’s persistent threat. Compounding the challenge is the absence of approved vaccines or treatments for the Nipah virus, underscoring the pressing need for innovative solutions.

Nipah Virus: A Global Concern

With its high mortality rate and the potential for widespread transmission, the Nipah virus looms large as a global health concern. Recognized as a priority pandemic pathogen, the virus significantly threatens public health infrastructure and community well-being. As such, efforts to develop effective vaccines and preventive strategies take on added urgency, aiming to mitigate local outbreaks and bolster preparedness for potential global pandemics.

CEPI Funding and Strategic Approach

The Coalition for Epidemic Preparedness Innovations (CEPI) is driving these crucial vaccine trials, a global partnership at the forefront of pandemic preparedness efforts. CEPI’s unwavering support underscores the collective commitment to combating infectious diseases and safeguarding public health worldwide. Leveraging the successful ChAdOx1 platform—a viral vector vaccine technology pivotal in developing the Oxford/AstraZeneca COVID-19 vaccine—reflects a strategic approach to addressing emerging viral threats. Researchers aim to accelerate progress towards effective Nipah virus vaccines and countermeasures by building upon past successes and harnessing innovative technologies.

Charting the Course for the Future

As the first human trials for the ChAdOx1 NipahB vaccine get underway, researchers embark on an 18-month rigorous evaluation and assessment journey. The trials, involving 51 participants aged 18 to 55, mark a significant milestone in the quest for effective Nipah virus vaccines. With further studies anticipated in Nipah-affected regions, the research community remains steadfast in its commitment to advancing scientific knowledge and translating discoveries into tangible solutions. The outcomes of these trials promise to provide much-needed defense against the Nipah virus, offering hope to vulnerable communities worldwide in the ongoing battle against infectious diseases. Stay tuned for updates on this groundbreaking research as researchers continue to push the boundaries of scientific innovation in pursuit of a safer, healthier future for all.

Disclaimer Statement: This information is from a third-party health news channel. The opinions expressed here belong to the respective authors/entities and do not reflect the views of Docquity. Docquity does not assure, endorse, or vouch for any of the content and bears no responsibility for it in any way. It is essential to take all necessary steps to ensure the information and content provided are accurate, current, and verified. Docquity disclaims any express or implied warranties related to the report and its contents.


First in-human vaccine trial for Nipah virus [Internet]. [cited 2024 Feb 5]. Available from:

About Docquity

If you need more confidence and insights to boost careers in healthcare, expanding the network to other healthcare professionals to practice peer-to-peer learning might be the answer. One way to do it is by joining a social platform for healthcare professionals, such as Docquity

Docquity is an AI-based state-of-the-art private & secure continual learning network of verified doctors, bringing you real-time knowledge from thousands of doctors worldwide. Today, Docquity has over 400,000 doctors spread across six countries in Asia. Meet experts and trusted peers across Asia where you can safely discuss clinical cases, get up-to-date insights from webinars and research journals, and earn CME/CPD credits through certified courses from Docquity Academy. All with the ease of a mobile app available on Android & iOS platforms!

Share it with

Similar Articles

Data Privacy Notice

This Privacy Notice shall be read in conjunction with the Privacy Policy to the extent this Notice does not mention or specify the particulars that should have been mentioned or specified relating to the Notice in pursuance of the provisions of the Data Protection Laws as applicable.

On having accessed or visited this Platform you the Noticee hereby voluntarily consent to and take notice of the fact that the personal data, by which or in relation whereto you the concerned Noticee is identifiable, shall be retained, stored, used, and may be processed by the Company for the purpose and in the manner, though legal, found suitable to it for commercial and/or some other reasons. The detailed specificity whereof may be found in the Privacy Policy. The consent provided herein may be withdrawn anytime by you, the Noticee, at its own volition by removing your profile or by writing to us at

As a Noticee, you shall have the right to grievance redressal, in relation to your consent or our use of your personal data, which you may address by writing to us at Should you, the Noticee, thereafter remain unsatisfied or dissatisfied with the resolution provided by us, you, the Noticee, may approach the concerned regulatory authority for the redressal of your grievance.

Thanks for exploring our medical content.

Create your free account or log in to continue reading.

Data Privacy Notice

By using this platform, you consent to our use of your personal data as detailed in our Privacy Policy, and acknowledge that we use cookies to improve your browsing experience